|
|
|
|
|
| Monocyte count-to-HDL cholesterol ratio with the recurrence of paroxysmal atrial fibrillation after catheter ablation |
| HU Xiao, ZHANG Jing, ZHOU Xue-jun, JI Yuan, LIU Yu, DING Zhi-jian |
| Department of Cardiovascular Medicine, Changzhou Second Hospital Affiliated of Nanjing Medical University, Changzhou 223001, China |
|
|
|
|
Abstract Objective To establish whether there is a relationship between monocyte count-to-HDL cholesterol ratio (MHR) and recurrence of paroxysmal atrial fibrillation (PAF) after catheter ablation. Methods Ninety-eight patients diagnosed with PAF from June 2011 to November 2014 in Chang⁃zhou Second Hospital were analyzed. Post-ablation blanking period was observed for three months, at a mean follow-up of (18.1±5.2) months, 29 patients (29.6%) patients had recurrence of atrial fibrillation.The MHR values were measured at baseline, one week, and six months after operation. The risk factors were analyzed by the multivariate unconditional logistic regression analysis. Results The MHR at baseline and six months in the patients whose PAF had recurred were higher than those without recurrence(P＜0.05). There were significant differences in PAF history, age, white blood cell (WBC), monocyte count, HDL cholesterol, MHR, hypersensitive C- reative protein (hs- CRP), left atrial diameter (LAD)(P＜0.05). MHR was positively related with LAD (P＜0.05). Multivariate unconditional logistic regression analysis showed that PAF history (OR: 2.631, 95% CI: 1.093~6.335, P＝0.031) and LAD (OR:2.591, 95%CI: 1.130~5.945, P＝0.025) were independent predictors of PAF recurrence after catheter ablation. Conclusion Increased pre-ablation MHR level is associated with a higher recurrence of PAF.MHR has a certain predictive value for postoperative recurrence of PAF but it suggests that other factors are also important.
|
|
Received: 17 November 2015
|
|
Corresponding Authors:
DING Zhi-jian, E-mail: dingzhijian@hotmail.com.cn
|
|
|
|
| [1] Calkins H，Kuck KH，Cappato R，et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection，procedural techniques，patient management and follow- up，definitions，end⁃points，and research trial design[J]. Europace，2012，14(4):528-606.
[2] Chao TF，Lin YJ，Chang SL，et al. Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation [J]. J Thorac Dis ，2015，7(2):172-177.
[3] Aksu T，Baysal E，Guler TE，et al. Predictors of atrial fibrillation recurrence after cryoballoon ablation[J]. J Blood Med，2015，6:211-217.
[4] Letsas KP，Weber R，Bürkle G，et al. Pre- ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation[J]. Europace，2009，11(2):158-163.
[5] Gurses KM，Yalcin MU，Kocyigit D，et al. Red blood cell distribution width predicts outcome of cryoballoon-based atrial fibrillation ablation[J]. J Interv Card Electrophysiol，2015，42(1):51-58.
[6] Friedrichs K，Klinke A，Baldus S. Inflammatory pathways underlying atrial fibrillation[J]. Trends Mol Med，2011，17(10):556-563.
[7] Watanabe H，Tanabe N，Yagihara N，et al. Association between lipid profile and risk of atrial fibrillation[J]. Circ J ，2011，75(12):2767-2774.
[8] Kanbay M，Solak Y，Unal HU，et al. Monocyte count/HDL choles⁃terol ratio and cardiovascular events in patients with chronic kidney disease[J]. Int Urol Nephrol，2014，46(8):1619-1625.
[9] European Heart Rhythm Association，European Association for Cardio-Thoracic Surgery，Camm AJ ，et al. Guidelines for the man⁃agement of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J].Europace，2010，12(10):1360-1420.
[10] Psychari SN，Apostolou TS，Sinos L，et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation[J]. Am J Cardiol，2005，95(6):764-767.
[11] Marcus GM，Smith LM，Ordovas K，et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation[J]. Heart Rhythm，2010，7(2):149-154.
[12] Burstein B，Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation[J]. J Am Coll Cardiol，2008，51(8):802-809.
[13] Galkina E，Ley K. Immune and inflammatory mechanisms of athero⁃sclerosis [J]. Annu Rev Immunol，2009，27:165-197.
[14] Fontes ML，Mathew JP，Rinder HM，et al. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation[J]. Anesth Analg，2005，101(1):17-23.
[15] Chimenti C，Russo MA，Carpi A，et al. Histological substrate of human atrial fibrillation[J]. Biomed Pharmacother，2010，64(3):177-183.
[16] Tokuda M，Yamane T，Matsuo S，et al. Relationship between renal function and the risk of recurrent atrial fibrillation following catheter ablation[J]. Heart，2011，97(2) :137-142.
[17] Ebong IA，Goff DC Jr，Rodriguez CJ，et al. Association of lipids with incident heart failure among adults with and without diabetes mellitus: Multiethnic Study of Atherosclerosis[J]. Circ Heart Fail，2013，6(3):371-378.
[18] Iguchi Y，Kimura K，Aoki J，et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan:analysis of 41，436 non- employee residents in Kurashiki- city[J].Circ J，2008，72(6):909-913.
[19] Díaz-Peromingo JA，Albán-Salgado A，García-Suárez F，et al. Li⁃poprotein(a) and lipid profile in patients with atrial fibrillation[J].Med Sci Monit，2006，12(3):CR122-125.
[20] Borggreve SE，De Vries R，Dullaart RP，et al. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes，lecithin:cholesterol acyltransferase and lipid transfer proteins[J]. Eur J Clin Invest，2003，33(12):1051-1069.
[21] Mora S，Akinkuolie AO，Sandhu RK，et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation[J]. Circ Arrhythm Electrophysiol，2014 ，7(4):612-619. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
